611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Long COVID Can Last a Year; Many Sufferers Quit JobsWould You Like Phthalates With That? Fast Food Contains Industrial Chemicals: ReportMany Blood Cancer Patients Get Little Protection From COVID VaccineMerck Allows Poor Nations to Make COVID-19 PillHow Folks Are Coping With Post-COVID Loss of Smell, TasteRoutine Ventilation of Surgical Patients Won't Raise COVID Transmission RiskImmunocompromised May Need Fourth COVID Shot: CDCLiver Transplants Soar as Some Americans Drink Their Way Through the PandemicFDA Advisors Approve Emergency Use of Pfizer COVID Vaccine in Kids 5 to 11COVID Vaccination Can Be Safe Even in People With Severe AllergiesTargeted High-Dose Radiation Helps Fight Advanced Lung CancerTrader Joe's Salami Snacks Tied to 20 Salmonella Cases in 8 StatesWhite House Takes More Steps to Boost Supply of Rapid at-Home COVID TestsBiden Administration Announces Details of Vaccination Requirements for Foreign TravelersAHA News: Never Heard of Sepsis? It's Common, Dangerous and a Threat to Your HeartModerna Says Its COVID Vaccine Works Well in Children Aged 6 to 11COVID Vaccination Does Not Raise Odds of Miscarriage: StudyVaccinated People Less Likely to Die of Any Cause in Months After Shots: CDCRecovering COVID Patients Often Face Long-Term 'Brain Fog'COVID Pandemic May Have Driven a Flu Strain Into ExtinctionThe No. 1 Cause of Halloween Injuries: Carving the PumpkinPfizer Vaccine Prevents 91% of Symptomatic COVID in Young Children: FDAPfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenDeadly Liver Disease Tied to Obesity Is on the RiseCDC Signs Off on Moderna, J&J Boosters, Backs Mix n' Match ShotsMoving Monoclonal Antibody Treatments for COVID From Hospital to HomeConfusion, Seizures: People Hospitalized After Taking Veterinary Drug for COVIDMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyPfizer Vaccine Booster Restores Nearly Full Protection, Company SaysTen Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune DiseaseSex of Fetus May Matter When COVID Strikes in PregnancyVaccines Cut Odds for Death From COVID Delta Variant by 90%U.S. Has Shared 200 Million Shots With Other CountriesSalmonella Outbreak in 37 States Linked to Imported OnionsFDA Approves Moderna, J&J Booster Shots, Backs Mix n' Match VaccinesWhite House Announces COVID Vaccination Plan for Young KidsEven With Mild COVID, Obesity May Mean Worse SymptomsNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsFlu Cases Already Up 23% This Season: WalgreensDoctors Report That Kidney Grown in Pig Worked in a HumanHeartburn Meds Might Be Good for Your GumsOne Big Factor for Survival After Spinal Cord Injury: ResilienceDying Young From Heart Disease: Where You Live in the U.S. MattersFDA Expected to Allow Mix n' Match COVID VaccinesPowell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsAHA News: Your Next Doctor's Prescription Might Be to Spend Time in NatureOut-of-Pocket Medical Bills for COVID-19 May Average $3,800 in 2021: StudyLegionnaires' Disease Outbreak Hits Long Island, N.Y.State Lotteries Didn't Help Boost Vaccination Rates
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Johnson & Johnson Seeks FDA Emergency Approval for Its Booster Shot

HealthDay News
by Robert Preidt and Robin Foster
Updated: Oct 5th 2021

new article illustration

TUESDAY, Oct. 5, 2021 (HealthDay News) -- Johnson & Johnson announced Tuesday that it has asked the U.S. Food and Drug Administration to approve emergency use of its coronavirus booster shot.

The request to authorize an extra vaccine dose for people who've previously received Johnson & Johnson's single-shot vaccine was filed Tuesday, the company said in a statement.

The company noted that it provided the FDA with data on booster intervals ranging from two to six months, but didn't formally recommend one to the agency.

"Our clinical program has found that a booster of our COVID-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent. We look forward to our discussions with the FDA and other health authorities to support their decisions regarding boosters," Dr. Mathai Mammen, global head of Janssen Research & Development, a subsidiary of Johnson & Johnson, said in the company's statement.

Last month, J&J released data suggesting its vaccine was 81% effective against hospitalizations at least five months after vaccination. An FDA advisory panel will review J&J's booster data next week and vote on whether to recommend boosters. The panel will do the same review for the Moderna booster shot during that meeting.

If both the FDA and the U.S. Centers for Disease Control and Prevention give their approval, booster shots of the two companies' COVID-19 vaccines could become available later this month, the AP reported.

The timing of the J&J filing was unusual because companies typically submit their requests well in advance of advisory panel meeting announcements.

But, "both J&J and FDA have a sense of urgency because it's COVID and we want good data out there converted into action as soon as possible," Mammen explained.

The J&J vaccine was originally considered an important tool in fighting the pandemic because it requires only one shot. But its rollout was hurt by a string of troubles, including manufacturing problems at a Baltimore factory that forced J&J to import millions of doses from overseas.

Federal regulators have also added warnings of some rare side effects that are linked to the shot, including a blood clot disorder and Guillain-Barré syndrome, the AP said. In both cases, regulators decided the benefits of the shot still outweighed those uncommon risks.

Rival drugmakers Pfizer and Moderna have provided the vast majority of COVID-19 vaccines to Americans. More than 170 million people have been fully vaccinated with the companies' two-dose shots, while less than 15 million Americans have gotten the J&J shot, the AP reported.

Last month, the FDA approved booster shots of Pfizer's vaccine for older people and other Americans at increased risk from severe COVID-19.

More information

Visit the U.S. Food and Drug Administration for more on COVID vaccines.


SOURCE: Associated Press